Model-based determination of abatacept exposure in support of the recommended dose for Japanese rheumatoid arthritis patients

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 38, Issue 6, 2011, Pages 803-832

  Hasegawa, Mayumi ^a,b   Imai, Yasuhiko ^a   Hiraoka, Masaki ^a   Ito, Kiyomi ^b   Roy, Amit ^c  

^a Pharmacometrics Research and Development   (Japan)

^b MUSASHINO UNIVERSITY   (Japan)

^c BRISTOL MYERS SQUIBB   (United States)

Author keywords

Abatacept; ACR20; Population PK; Rheumatoid arthritis; Trough concentration

Indexed keywords

ABATACEPT; METHOTREXATE; PLACEBO;

ADULT; ARTICLE; BODY WEIGHT; COMPARTMENT MODEL; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; POPULATION MODEL; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RHEUMATOID ARTHRITIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOCONJUGATES; INFUSIONS, INTRAVENOUS; LOGISTIC MODELS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL;

EID: 84855708394     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-011-9221-5     Document Type: Article

References (37)

1. Genovese MC, Becker J-C, Schiff M, Luggen M, Sherrer Y, Kremer J, Birbara C, Box J, Natarajan K, Nuamah I, Li T, Aranda R, Hagerty DT, Dougados M (2005) Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 353:1114-1123 (Pubitemid 41317434)
2. Abrams JR, Lebwohl MG, Guzzo CA, Jegasothy BV, Goldfarb MT, Goffe BS, Menter A, Lowe NJ, Krueger G, Brown MJ, Weiner RS, Birkhofer MJ, Warner GL, Berry KK, Linsley PS, Krueger JG, Ochs HD, Kelley SL, Kang S (1999) CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 103:1243-1252 (Pubitemid 29218294)
3. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, Russell A, Dougados M, Emery P, Nuamah IF, Williams GR, Becker J-C, Hagerty DT, Moreland LW (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907-1915 (Pubitemid 37409707)
4. Goldring SR (2002) Pathogenesis of bone erosions in rheumatoid arthritis. Curr Opin Rheumatol 14:406-410 (Pubitemid 34693986)
5. Hoffman RW (2001) T cells in the pathogenesis of systemic lupus erythematosus. Front Biosci 6:D1369-D1378
6. Goronzy JJ, Weyand CM (2004) T-cell regulation in rheumatoid arthritis. Curr Opin Rheumatol 16:212-217 (Pubitemid 38530488)
7. Lenschow DJ, Walunas TL, Bluestone JA (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14:233-258 (Pubitemid 26130184)
8. Silver PB, Hathcock KS, Chan CC, Wiggert B, Caspi RR (2000) Blockade of costimulation through B7/CD28 inhibits experimental autoimmune uveoretinitis, but does not induce long-term tolerance. J Immunol 165:5041-5047
9. Choy EH, Panayi GS (2001) Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344:907-916 (Pubitemid 32224400)
10. Maxwell LJ, Singh JA (2010) Abatacept for rheumatoid arthritis: A Cochrane systematic review. J Rheumatol 37:234-245
11. Ma Y, Lin B-R, Lin B, Hou S, Qian W-Z, Li J, Tan M, Ma J, Li B-H, Wang H, Wen A-D, Guo Y-J (2009) Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. Acta Pharmacol Sin 30:364-371
12. Davis PM, Nadler SG, Rouleau KA, Suchard SJ (2005) Abatacept (CTLA4-Ig) modulates human T-cell proliferation and cytokine production but does not affect lipopolysaccharide-induced tumor necrosis factor alpha production by monocytes. Arthritis Res Ther 7(suppl 1):21
13. Roy A, Mould DR, Wang XF, Tay L, Raymond R, Pfister M (2007) Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacol 47:1408-1420 (Pubitemid 47624599)
14. ICON (2007) NONMEM7 TM user's guide. http://www.globomaxnm.com/nonmem. htm. Accessed Mar 2011
15. Harrell FE Jr, Lee KL, Califf RM, Pryor DB, Rosati RA (1984) Regression modeling strategies for improved prognostic prediction. Stat Med 3:143-152 (Pubitemid 14052973)
16. Bradburn MJ, Clark TG, Love SB, Altman DG (2003) Survival analysis part III: Multivariate data analysis-choosing a model and assessing its adequacy and fit. Br J Cancer 89:605-611 (Pubitemid 37076159)
17. Levey AS, Coresh J, Greene T, Marsh J, Stevens LA, Kusek JW, Van Lente F (2007) Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 53:766-772 (Pubitemid 46580250)
18. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Hara S, Ura N, Kiyohara Y, Hirakata H, Watanabe T, Moriyama T, Ando Y, Inaguma D, Narita I, Iso H, Wakai K, Yasuda Y, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S (2007) Estimation of glomerular filtration rate by the MDRD study equation modified for Japanese patients with chronic kidney disease. Clin Exp Nephrol 11:41-50 (Pubitemid 46474965)
19. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV (2003) Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 43:610-623 (Pubitemid 36613120)
20. Liang KY, Zeger SL (1986) Longitudinal data analysis using generalized linear models. Biometrika 73:13-22
21. Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC (2003) Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 73:348-365 (Pubitemid 36403595)
22. Pan W (2001) Akaike's information criterion in generalized estimating equations. Biometrics 57:120-125 (Pubitemid 32200145)
23. Yasuoka Y, Goto A, Seriu T (2011) Pharmacological properties and clinical efficacy of abatacept (Orencia®) for the treatment of rheumatoid arthritis. Nippon Yakurigaku Zasshi 137:87-94 Japanese
24. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G (2008) Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 30:523-529
25. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, Teoh LS, Velagapudi RB, Noertersheuser PA, Granneman GR, Fischkoff SA, Chartash EK (2003) Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factoralpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: A pilot study. Clin Ther 25:1700-1721 (Pubitemid 36801943)
26. Bristol-Myers K.K. (2010) Orencia (abatacept) [prescribing information]. http://www.orencia.jp. Accessed Mar 2011
27. Dowell JA, Korth-Bradley J, Liu H, King SP, Berger MS (2001) Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol 41:1206-1214 (Pubitemid 32983219)
28. Tang L, Persky AM, Hochhaus G, Meibohm B (2004) Pharmacokinetic aspects of biotechnology products. J Pharm Sci 93:2184-2204 (Pubitemid 39129617)
29. Lobo ED, Hansen RJ, Balthasar JP (2004) Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668 (Pubitemid 39506617)
30. Sun YN, Lu JF, Joshi A, Compton P, Kwon P, Bruno RA (2005) Population pharmacokinetics of efalizumab (humanized monoclonal anti-CD11a antibody) following long-term subcutaneous weekly dosing in psoriasis subjects. J Clin Pharmacol 45:468-476 (Pubitemid 40490420)
31. Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic/ pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28:171-192
32. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, Paulus H, Tugwell P, Weinblatt M, Widmark R, Williams HJ, Wolfe F (1993) The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 36:729-740 (Pubitemid 23175613)
33. Hempel G, Karlsson MO, de Alwis DP, Toublanc N, McNay J, Schaefer HG (1998) Population pharmacokinetic-pharmacodynamic modeling of moxonidine using 24-hour ambulatory blood pressure measurements. Clin Pharmacol Ther 64:622-635 (Pubitemid 29011382)
34. Trocóniz IF, de Alwis DP, Tillmann C, Callies S, Mitchell M, Schaefer HG (2000) Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic-pharmacodynamic modeling of antihypertensive compounds: Application to moxonidine. Clin Pharmacol Ther 68:18-27 (Pubitemid 30609823)
35. Mandema JW, Stanski DR (1996) Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 60:619-635 (Pubitemid 27025909)
36. Holford NH, Peace KE (1992) Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 89:11466-11470
37. Gomeni R, Teneggi V, Iavarone L, Squassante L, Bye A (2001) Population pharmacokinetic-pharmacodynamic model of craving in an enforced smoking cessation population: Indirect response and probabilistic modeling. Pharm Res 18:537-543 (Pubitemid 32592588)